Computational repositioning and experimental validation of approved drugs for HIF-prolyl hydroxylase inhibition

Journal of Chemical Information and Modeling

Volumn 53, Issue 7, 2013, Pages 1818-1824

  Teli, Mahesh Kumar ^a   Rajanikant, G K ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY CALICUT   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MACHINERY; SURVEYS;

CYTOPROTECTION; EXPERIMENTAL TESTING; EXPERIMENTAL VALIDATIONS; ISCHEMIA/REPERFUSION; LITERATURE SURVEY; PROLYL HYDROXYLASE; PROTECTIVE EFFECTS; VIRTUAL SCREENING;

DOCKING;

ENZYME INHIBITOR; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG APPROVAL; HUMAN; PROTEIN CONFORMATION; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS;

DRUG APPROVAL; ENZYME INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84880545825     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400254a     Document Type: Article

References (37)

1. Fan, X.; Heijnen, C. J.; van-der-Kooij, M. A.; Groenendaal, F.; van-Bel, F. The role and regulation of hypoxia-inducible factor-1α expression in brain development and neonatal hypoxic-ischemic brain injury Brain Res. Rev. 2009, 62, 99-108
2. Semenza, G. L. Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 2003, 3, 721-732
3. Wenger, R. H.; Stiehl, D. P.; Camenisch, G. Integration of oxygen signaling at the consensus HRE Sci. Signaling 2005, 306, re12
4. Elvidge, G. P.; Glenny, L.; Appelhoff, R. J.; Ratcliffe, P. J.; Ragoussis, J.; Gleadle, J. M. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate dependent dioxygenase inhibition; the role of HIF-1α, HIF-2α and other pathways J. Biol. Chem. 2006, 281, 15215-15226
5. Miyata, T.; Takizawa, S.; van, Y.; persele-de-Strihou, C. Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets Am. J. Physiol. Cell Physiol. 2011, 300, C226-C231
6. Koeppen, M.; Eckle, T.; Eltzschig, H. K. The hypoxia-inflammation link and potential drug targets Curr. Opin. Anaesthesiol. 2011, 24, 363-369
7. Sen-Banerjee, S.; Thirunavukkarasu, M.; Tipu, R. M.; Sanchez, J. A.; Maulik, N.; Maulik, G. HIF-prolyl hydroxylases and cardiovascular diseases Toxicol. Mech. Methods 2012, 22, 347-358
8. Gidday, J. M.; Fitzgibbons, J. C.; Shah, A. R.; Park, T. S. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat Neurosci. Lett. 1994, 168, 221-224
9. Miller, B. A.; Perez, R. S.; Shah, A. R.; Gonzales, E. R.; Park, T. S.; Gidday, J. M. Cerebral protection by hypoxic preconditioning in a murine model of focal ischemia-reperfusion NeuroReport 2001, 12, 1663-1669
10. Ran, R.; Xu, H.; Lu, A.; Bernaudin, M.; Sharp, F. R. Hypoxia preconditioning in the brain Dev. Neurosci. 2005, 27, 87-92
11. Siddiq, A.; Aminova, L. R.; Troy, C. M.; Suh, K.; Messer, Z.; Semenza, G. L.; Ratan, R. R. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways J. Neurosci. 2009, 29, 8828-8838
12. Teli, M. K.; Rajanikant, G. K. Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening Mol. Divers. 2012, 16, 193-202
13. Bernhardt, W. M.; Wiesener, M. S.; Scigalla, P.; Chou, J.; Schmieder, R. E.; Günzler, V.; Eckardt, K. U. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD J. Am. Soc. Nephrol. 2010, 21, 2151-2156
14. Issa, N. T.; Kruger, J.; Byers, S. W.; Dakshanamurthy, S. Drug repurposing a reality: From computers to the clinic Expert Rev. Clin. Pharmacol. 2013, 6, 95-97
15. Teli, M. K.; Krishnamurthy, R. G. A combination of 3D-QSAR modeling and molecular docking approach for the discovery of potential HIF prolyl hydroxylase inhibitors Med. Chem. 2013, 9, 360-370
16. Teli, M. K.; Krishnamurthy, R. G. Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors Org. Med. Chem. Lett. 2012, 2, 25
17. Teli, M. K.; Rajanikant, G. K. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors J. Enzyme Inhib. Med. Chem. 2012, 27, 558-570
18. Glide, version 5.5, Schrödinger, LLC, New York, 2009.
19. Schrödinger Suite 2009 Protein Preparation Wizard; Epik version 2.0, Schrödinger, LLC, New York, 2009.
20. Impact, version 5.5, Schrödinger, LLC, New York, 2009
21. Prime, version 2.1, Schrödinger, LLC, New York, 2009.
22. Takeda, N.; Gotoh, M.; Matsuoka, T. Rapid screening method for quinolone residues in livestock and fishery products using immobilised metal chelate affinity chromatographic clean-up and liquid chromatography-fluorescence detection Food Addit. Contam., Part A. 2011, 28, 1168-1174
23. Yamabe, S. The effect of nalidixic acid group compounds on reduction of cytochrome c from horse heart and Candida krusei J. Gen. Microbiol. 1978, 105, 227-232
24. Flagg, S. C.; Martin, C. B.; Taabazuing, C. Y.; Holmes, B. E.; Knapp, M. J. Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH) J. Inorg. Biochem. 2012, 113, 25-30
25. Li, Y.; Zhang, P. J.; Jin, C.; Zhou, B.; Liu, X. Y.; Tao, L. D.; Feng, M. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver auto transplantation in rats Transplant Proc. 2011, 43, 1450-1455
26. Tagliari, B.; Zamin, L. L.; Salbego, C. G.; Netto, C. A.; Wyse, A. T. Hyperhomocysteinemia increases damage on brain slices exposed to in vitro model of oxygen and glucose deprivation: Prevention by folic acid Int. J. Dev. Neurosci. 2006, 24, 285-291
27. Carletti, J. V.; Deniz, B. F.; Miguel, P. M.; Rojas, J. J.; Kolling, J.; Scherer, E. B.; de-Souza-Wyse, A. T.; Netto, C. A.; Pereira, L. O. Folic acid prevents behavioral impairment and Na(+), K(+) -ATPase inhibition caused by neonatal hypoxia-ischemia Neurochem. Res. 2012, 37, 1624-1630
28. Moreira, D. M.; Vieira, J. L.; Gottschall, C. A. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: A randomized double-blind, placebo-controlled trial (METIS trial) J. Card. Fail. 2009, 15, 828-834
29. Cronstein, B N. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis Pharmacol. Rev. 2005, 57, 163-172
30. Sadiq, S. A.; Simon, E. V.; Puccio, L. M. Intrathecal methotrexate treatment in multiple sclerosis J. Neurol. 2010, 257, 1806-1811
31. Sala-Mercado, J. A.; Wider, J.; Undyala, V. V.; Jahania, S.; Yoo, W.; Mentzer, R. M.; Gottlieb, R. A.; Przyklenk, K. Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury Circulation 2010, 122, S179-184
32. Granville, D. J.; Tashakkor, B.; Takeuchi, C.; Gustafsson, A. B.; Huang, C.; Sayen, M. R.; Wentworth, P., Jr.; Yeager, M.; Gottlieb, R. A. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors Proc. Natl. Acad. Sci. U.S.A. 2004, 5, 1321-1326
33. 2 Biochem. Pharmacol. 2013, 85, 1153-1161
34. Alleva, R.; Borghi, B.; Santarelli, L.; Strafella, E.; Carbonari, D.; Bracci, M.; Tomasetti, M. In vitro effect of aspartame in angiogenesis induction Toxicol. In Vitro 2011, 25, 286-293
35. Manion, C. V.; Howard, J.; Ogle, B.; Parkhurst, J.; Edmundson, A. Aspartame effect in sickle cell anemia Clin. Pharmacol. Ther. 2001, 69, 346-355
36. DeLellis, S. M.; Anderson, S. E.; Lynch, J. H.; Kratz, K. Acute mountain sickness prophylaxis: A high-altitude perspective Curr. Sports Med. Rep. 2013, 12, 110-114
37. Xu, J.; Peng, Z.; Li, R.; Dou, T.; Xu, W.; Gu, G.; Liu, Y.; Kang, Z.; Tao, H.; Zhang, J. H.; Ostrowski, R. P.; Lu, J.; Sun, X. Normoxic induction of cerebral HIF-1alpha by acetazolamide in rats: Role of acidosis Neurosci. Lett. 2009, 451, 274-278